Taysha Gene Therapies, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TSHA research report →
Companywww.tayshagtx.com
Taysha Gene Therapies, Inc. , a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
- CEO
- Sean Nolan
- IPO
- 2020
- Employees
- 73
- HQ
- Dallas, TX, US
Price Chart
Valuation
- Market Cap
- $1.37B
- P/E
- -15.50
- P/S
- 160.13
- P/B
- 9.50
- EV/EBITDA
- -7.20
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 88.22%
- Op Margin
- -1774.37%
- Net Margin
- -1738.40%
- ROE
- -56.07%
- ROIC
- -47.30%
Growth & Income
- Revenue
- $9.77M · 17.28%
- Net Income
- $-108,995,000 · -22.06%
- EPS
- $-0.34 · 5.56%
- Op Income
- $-110,498,000
- FCF YoY
- -14.99%
Performance & Tape
- 52W High
- $7.30
- 52W Low
- $2.25
- 50D MA
- $5.42
- 200D MA
- $4.58
- Beta
- 1.23
- Avg Volume
- 2.80M
Get TickerSpark's AI analysis on TSHA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 10, 26 | Nagendran Sukumar | other | 19,021 |
| Apr 10, 26 | Nagendran Sukumar | sell | 200,000 |
| Apr 10, 26 | Nagendran Sukumar | other | 19,021 |
| Feb 4, 26 | Alam Kamran | sell | 1,655 |
| Jan 23, 26 | Nagendran Sukumar | sell | 89,132 |
| Jan 26, 26 | Nagendran Sukumar | sell | 26,918 |
| Jan 23, 26 | Nolan Sean P. | sell | 136,789 |
| Jan 26, 26 | Nolan Sean P. | sell | 41,312 |
| Jan 23, 26 | Alam Kamran | sell | 78,968 |
| Jan 26, 26 | Alam Kamran | sell | 23,849 |
Our TSHA Coverage
We haven't published any research on TSHA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TSHA Report →